Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H1 2016', provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - The report reviews Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Overview 6 Therapeutics Development 7 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Stage of Development 7 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Therapy Area 8 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Indication 9 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Companies 12 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Companies Involved in Therapeutics Development 20 AbbVie Inc. 20 Handok Inc. 21 XBiotech USA, Inc. 22 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Drug Profiles 23 ABT-981 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CV-18C3 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HL-2351 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 RA-18C3 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 T2-18C3 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Xilonix - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Dormant Projects 36 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Featured News & Press Releases 37 Jun 08, 2016: Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Companys Extensive Product Portfolio 37 May 24, 2016: XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer 37 Apr 19, 2016: XBiotech to Present Pivotal Phase 3 Data on Xilonix at European Society of Medical Oncology's World Congress on Gastrointestinal Cancer 38 Apr 04, 2016: European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix, XBiotech's True Human Therapeutic Antibody Treatment for Advanced Colorectal Cancer 39 Mar 23, 2016: XBiotech Announces European Medicines Agency Validates Marketing Authorization Application for Xilonix in the Treatment of Advanced Colorectal Cancer 39 Mar 08, 2016: XBiotech Announces Submission of Marketing Authorization Application for Candidate Colorectal Cancer Therapy to European Medicines Agency 40 Mar 04, 2016: European Medicines Agency Grants Eligibility for Submission of XBiotech's Marketing Authorization Application 41 Mar 02, 2016: XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix During Meeting at the European Parliament 42 Jan 21, 2016: XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium 42 Jan 08, 2016: XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix in Advanced Colorectal Cancer 43 Dec 07, 2015: XBiotech Announces Positive Results in European Phase III Study for Its Breakthrough Therapy for Colorectal Cancer 44 Nov 23, 2015: XBiotech Provides Update on Phase III Oncology Study in Europe 45 Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting 46 Oct 02, 2015: XBiotech Announces Publication of Clinical Results Supporting the Potential of Its True Human Antibody as a Cardiovascular Therapy 46 Aug 17, 2015: XBiotech Completes Enrollment for Xilonix Phase III Registration Study in Europe 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by AbbVie Inc., H1 2016 20 Pipeline by Handok Inc., H1 2016 21 Pipeline by XBiotech USA, Inc., H1 2016 22 Dormant Projects, H1 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
